VAX-31 OPUS-1 results indicate broader coverage with 2028 BLA anticipated
Oct 5, 2026, 6:32 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive OPUS-1 topline data strengthens Vaxcyte’s pathway to broader pneumococcal coverage; near-term catalysts (OPUS-2/OPUS-3 in 1H 2027) could drive sentiment and multiple expansion for PCVX, while the 2028 BLA timeline provides a defined regulatory path. Historically, similar Phase 3 readouts have supported post-announcement rallies in biotech vaccine developers when endpoints align with strong safety signals.
AI summary
What happened, with direct paths to the underlying reporting
OPUS-1 topline results show VAX-31 meets noninferiority across major serotypes and demonstrates superiority for three unique types, with a safety profile similar to PCV20/PCV21. Management targets a 2028 BLA submission, with OPUS-2 and OPUS-3 Phase 3 results due in 1H 2027. If FDA review remains favorable, VAX-31 could broaden pneumococcal vaccination in adults.
OPUS-1: VAX-31 met noninferiority for 28 serotypes shared with PCV20/PCV21.
Three unique serotypes and cross-reactive 20B showed superiority against comparators.
Immunobridging: noninferiority across 321 serotype comparisons (18-49 vs 50-64).
Safety: VAX-31 well tolerated, safety profile similar to PCV20/PCV21.
Upcoming catalysts: OPUS-2/OPUS-3 data in 1H 2027; BLA planned 1H 2028.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
